- Sections
- C - Chimie; métallurgie
- C07K - Peptides
- C07K 14/135 - Virus respiratoire syncytial
Détention brevets de la classe C07K 14/135
Brevets de cette classe: 183
Historique des publications depuis 10 ans
7
|
5
|
16
|
12
|
17
|
12
|
14
|
8
|
13
|
7
|
2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
Propriétaires principaux
Proprétaire |
Total
|
Cette classe
|
---|---|---|
The United States of America, as represented by the Secretary, Department of Health and Human Services | 2737 |
16 |
Janssen Vaccines & Prevention B.V. | 337 |
13 |
Glaxosmithkline Biologicals S.A. | 1701 |
12 |
Institute for Research in Biomedicine | 95 |
10 |
Pfizer Inc. | 3322 |
5 |
ID Biomedical Corporation of Quebec | 37 |
5 |
Institut National de La Recherche Agronomique (inra) | 171 |
4 |
Fondation The Ark | 5 |
4 |
Board of Regents, The University of Texas System | 5370 |
3 |
The Pirbright Institute | 49 |
3 |
Research Institute at Nationwide Children's Hospital | 481 |
3 |
University of Massachusetts | 2130 |
3 |
University of Washington | 2157 |
3 |
Meissa Vaccines, Inc. | 14 |
3 |
Novartis AG | 11238 |
2 |
Merck Sharp & Dohme Corp. | 2247 |
2 |
National Taiwan University | 1140 |
2 |
Crucell Holland B.V. | 121 |
2 |
Georgia State University Research Foundation, Inc. | 332 |
2 |
Humabs Biomed SA | 115 |
2 |
Autres propriétaires | 84 |